Or assessing spatial and related forms of Mikamycin BMedChemExpress Mikamycin IA learning and memory. Nat
Or assessing spatial and related forms of learning and memory. Nat Protoc. 2006;1(2):848?8. Fang F, Lue LF, Yan S, Xu H, Luddy JS, Chen D, Walker DG, Stern DM, Yan S, Schmidt AM. RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/27196668 in a mouse model of Alzheimer’s disease. FASEB J. 2010;24(4):1043?5. Lou G, Zhang Q, Xiao F, Xiang Q, Su Z, Zhang L, Yang P, Yang Y, Zheng Q, Huang Y. Intranasal administration of TAT-haFGF attenuates disease progression in a mouse model of Alzheimer’s disease. Neuroscience. 2012;223:225?7. Shi YQ, Huang TW, Chen LM, Pan XD, Zhang J, Zhu YG, Chen XC. Ginsenoside Rg1 attenuates amyloid-beta content, regulates PKA/CREB activity, and improves cognitive performance in SAMP8 mice. J Alzheimers Dis. 2010;19(3):977?9. Cheng XR, Yang Y, Zhou WX, Zhang YX. Expression of VGLUTs contributes to degeneration and acquisition of learning and memory. Neurobiol Learn Mem. 2011;95(3):361?5. Cheng X, Zhou Y, Gu W, Wu J, Nie A, Cheng J, Zhou J, Zhou W, Zhang Y. The selective BACE1 inhibitor VIa reduces amyloid-beta production in cell and mouse models of Alzheimer’s disease. J Alzheimers Dis. 2013;37(4):823?4. Tesseur I, Pimenova AA, Lo AC, Ciesielska M, Lichtenthaler SF, De Maeyer JH, Schuurkes JA, D’Hooge R, De Strooper B. Chronic 5-HT4 receptor activation decreases Abeta PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/25768400 production and deposition in hAPP/PS1 mice. Neurobiol Aging. 2013;34(7):1779?9. Swanwick GR, Kirby M, Bruce I, Buggy F, Coen RF, Coakley D, Lawlor BA. Hypothalamic-pituitary-adrenal axis dysfunction in Alzheimer’s disease: lack of association between longitudinal and cross-sectional findings. Am J Psychiatry. 1998;155(2):286?. McGonigal G, Thomas B, McQuade C, Starr JM, MacLennan WJ, Whalley LJ. Epidemiology of Alzheimer’s presenile dementia in Scotland, 1974?8. BMJ. 1993;306(6879):680?. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88(9):1337?2. Fratiglioni L, Viitanen M, von Strauss E, Tontodonati V, Herlitz A, Winblad B. Very old women at highest risk of dementia and Alzheimer’s disease: incidence data from the Kungsholmen Project, Stockholm. Neurology. 1997;48(1):132?. Smith MA, Perry G, Atwood CS, Bowen RL. Estrogen replacement and risk of Alzheimer disease. Jama. 2003;289(9):1100. author reply 1101?102. Sierksma AS, van den Hove DLA, Rutten K, Chouliaras L, Rostamian S, Steinbusch HWM, Prickaerts J. Chronic phosphodiesterase type 2 inhibition improves spatial memory and alters synaptic density in the hippocampus in the APPswe/PS1dE9 mouse model of Alzheimer’s disease. Neuropharmacology. 2013;64(1):124?36. Carroll JC, Iba M, Bangasser DA, Valentino RJ, James MJ, Brunden KR, Lee VM, Trojanowski JQ. Chronic stress exacerbates tau pathology, neurodegeneration, and cognitive performance through a corticotropin-releasing factor receptordependent mechanism in a transgenic mouse model of tauopathy. J Neurosci. 2011;31(40):14436?9. Dong H, Yuede CM, Yoo HS, Martin MV, Deal C, Mace AG, Csernansky JG. Corticosterone and related receptor expression are associated with increased beta-amyloid plaques in isolated Tg2576 mice. Neuroscience. 2008;155(1):154?3. Horgan J, Miguel-Hidalgo JJ, Thrasher M, Bissette G. Longitudinal brain corticotropin releasing factor and somatostatin in a transgenic mouse (TG2576) model of Alzheimer’s disease. J Alzheimers Dis. 2007;12(2):115?7. Guo Q, Zhen.